SCHEMBL6318407

SCHEMBL6318407

[CH2]N(C)CC(O)c1ccc(CN(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HRH3 Q9Y5N1 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
AOC3 Q16853 6/20 0.44
TAAR1 Q96RJ0 2/20 0.44
CNR2 P34972 1/20 0.41
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
POLB P06746 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HTR2A P28223 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318414 0.87 HRH3 (0.50) KDM4EMEN1KMT2ASMN1; SMN2HRH3
SCHEMBL6320185 0.84 AOC3 (0.46) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6320570 0.79 TAAR1 (0.50) KDM4ESMN1; SMN2ALDH1A1TSHRAOC3
SCHEMBL6320678 0.79 KDM4E (0.57) KDM4EMEN1KMT2ASMN1; SMN2HRH3
SCHEMBL6284970 0.79 AOC3 (0.68) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6281298 0.78 AOC3 (0.68) KDM4EMEN1KMT2ASMN1; SMN2AOC3
SCHEMBL6281260 0.78 AOC3 (0.68) KDM4EMEN1KMT2ASMN1; SMN2AOC3
SCHEMBL6319229 0.75 KDM4E (0.59) KDM4EMEN1KMT2ASMN1; SMN2HRH3
SCHEMBL6479386 0.75 AOC3 (0.70) ALDH1A1AOC3POLBSLC6A2SLC6A4
SCHEMBL31003251 0.75 HRH3 (0.54) KDM4EMEN1KMT2ASMN1; SMN2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852731-B2 Antiviral compounds PFIZER (US) 2005-02-08 US claimed
US-20040242884-A1 ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY 2004-12-02 US claimed
EP-1472260-A2 THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 EP claimed
WO-2003059878-A2 THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242884-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, IRF3, IFNAR1 KDM4E 1156/4885MEN1 1462/4885KMT2A 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.